Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Brawn Biotech's Board of Directors met on September 2, 2025 and approved several routine matters. The Board approved alterations to the existing Memorandum of Association to align it with the Companies Act, 2013, though there is no change in the main objects of the company. The 40th Annual General Meeting was scheduled for September 30, 2025, to be held via video conferencing. The Board also approved the Board's Report for the financial year ended March 31, 2025, and re-appointed Mr. Amit Kumar as Manager for a further period of 5 years, effective February 12, 2026 to February 11, 2031.
This is a routine administrative filing with no major impact on shareholders or the stock price. The MOA changes are procedural with no change in business objects, and the AGM and director re-appointment are standard annual corporate actions.